Philip Ashton-Rickardt
Technik-/Wissenschafts-/F&E-Leiter bei SIGILON THERAPEUTICS, INC.
Vermögen: - $ am 31.07.2023
Aktive Positionen von Philip Ashton-Rickardt
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| SIGILON THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 14.06.2021 | - |
Karriereverlauf von Philip Ashton-Rickardt
Ehemalige bekannte Positionen von Philip Ashton-Rickardt
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
AZTherapies, Inc.
 AZTherapies, Inc. Pharmaceuticals: MajorHealth Technology AZTherapies, Inc. engages in the development of therapeutics for Alzheimer’s disease and ischemic stroke treatments. Its product pipelines include ALZT-OP1, ALZT-OP2, AZHALER-D, and ALZT-QoL. The company was founded by David R. Elmaleh in 2011 and is headquartered in Boston, MA. | Corporate Officer/Principal | 01.01.2019 | 01.06.2021 |
Smith Therapeutics, Inc.
 Smith Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Smith Therapeutics, Inc. operates as a biopharmaceutical firm which treats neurodegenerative disease. The company was founded by Philip Ashton-Rickardt in 2017 and is headquartered in Chestnut, MA. | Direktor/Vorstandsmitglied | 01.01.2017 | 31.10.2019 |
| Vorstandsvorsitzender | 01.01.2017 | 31.10.2019 | |
| Gründer | 01.01.2017 | 31.10.2019 | |
| Präsident | 01.01.2017 | 31.10.2019 | |
| Unternehmenssekretär | 01.01.2017 | 31.10.2019 | |
| The University of Chicago | Corporate Officer/Principal | 01.06.1995 | 01.06.2006 |
| Imperial College London | Corporate Officer/Principal | - | - |
Ausbildung von Philip Ashton-Rickardt
| The University of Edinburgh | Doctorate Degree |
| King's College London | Undergraduate Degree |
Statistik
International
| Vereinigte Staaten | 5 |
| Vereinigtes Königreich | 4 |
Operativ
| Corporate Officer/Principal | 3 |
| Director/Board Member | 1 |
| Chief Executive Officer | 1 |
Sektoral
| Consumer Services | 5 |
| Health Technology | 4 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| SIGILON THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
AZTherapies, Inc.
AZTherapies, Inc. Pharmaceuticals: MajorHealth Technology AZTherapies, Inc. engages in the development of therapeutics for Alzheimer’s disease and ischemic stroke treatments. Its product pipelines include ALZT-OP1, ALZT-OP2, AZHALER-D, and ALZT-QoL. The company was founded by David R. Elmaleh in 2011 and is headquartered in Boston, MA. | Health Technology |
Smith Therapeutics, Inc.
Smith Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Smith Therapeutics, Inc. operates as a biopharmaceutical firm which treats neurodegenerative disease. The company was founded by Philip Ashton-Rickardt in 2017 and is headquartered in Chestnut, MA. | Health Technology |
- Börse
- Insiders
- Philip Ashton-Rickardt
- Erfahrung
